期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

雷帕霉素联合ZD55-TRAIL病毒对肿瘤抑制及其机制探讨

The Experimental Study on Cytotoxic Effect of Oncolytic Virus ZD55-TRAIL Combined With Rapamycin against Human Cancer Cells and the Exploration Mechanism
原文传递
导出
摘要 溶瘤腺病毒的肿瘤靶向性研究一直是一个热点。目前已有商业化的ONYX-015、H101溶瘤腺病毒。在此基础上，科学家又进一步发展形成基因一病毒治疗方案，如文中应用的ZD55-TRAIL病毒。本研究利用刘新垣实验室提供的携带TRAIL（TNF-related apoptosis-inducing ligand，TNF相关的凋亡诱导配体）的溶瘤腺病毒ZD55-TRAILt^[1]联合雷帕霉素杀伤肿瘤细胞。ZD55-TRAIL是删除了腺病毒E1B-55KD， This research investigates the effect of combined application of oncolytic virus ZD55-TRAIL and the chemotherapeutic drugs Rapamycin （Rap） in growth inhibiton of human cancer cells in vitro. The effects of the treatment were measured by MTT assay and the replication of E1B-55KD deletion adenovirus was detected by the expression of E1A protein by Western blot. These observations suggest that Rapamycin could increase the levels of E1A, which may explain its ablitiy to enhance ZD55-TRAIL virus oncolysis. The combination therapy with signaling inhibitors that modulate activity of mTOR pathway will promote the cytotoxity against human cancer cells.
作者 刘锡君 李新 郑水娣 钟丹 章康健 王世兵 周秀梅
机构地区 浙江理工大学生命科学学院新元医学与生物技术研究所 中国科学院上海生命科学研究院生物化学与细胞生物学研究所
出处 《中国细胞生物学学报》 CAS CSCD 2011年第6期688-691,共4页 Chinese Journal of Cell Biology
基金 浙江理工大学科研启动基金(No.0916819-Y)资助项目~~
关键词 溶瘤腺病毒 雷帕霉素 肿瘤坏死因子相关的凋亡诱导配体 E4orf1 oncolytic virus Rapamycin TRAIL E4orf1
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献10

  • 1Zhao L, Dong A, Gu J, Liu Z, Zhang Y, Zhang W, et al. The an- titumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther 2006; 13(11): 1011-22.
  • 2O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, et al. Late viral RNA export, rather than p53 inactivation, de- termines ONYX-015 tumor selectivity. Cancer Cell 2004; 6(6): 611-23.
  • 3Opyrchal M, Aderca I, Galanis E. Phase 1 clinical trial of locore- gional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods Mol Biol 2009; 542: 705-17.
  • 4Yang Z, Lei Z, Li B, Zhou Y, Zhang GM, Feng ZH, et al. Ra- pamycin inhibits lung metastasis of B16 melanoma cells through down-regulating alphav integrin expression and up-regulating apoptosis signaling. Cancer Sci; 101 (2): 494-500.
  • 5Yang JM, Hung CM, Fu CN, Lee JC, Huang CH, Yang MH, et al. Hispidulin sensitizes human ovarian cancer cells to TRAIL- induced apoptosis by AMPK activation leading to Mcl-1 block in translation. J Agric Food Chem; 58(I 8): 10020-6.
  • 6Guertin DA, Sabatini DM. The pharmacology of mTOR inhibi- tion. Sci Signal 2009; 2(67): pe24.
  • 7Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Vil- laroel MC, et al. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Br J Cancer; 103(5): 649-55.
  • 8Thomas MA, Broughton RS, Goodrum FD, Omelles DA. E4orf1 limits the oncolytic potential of the E1B-55K deletion mutant adenovirus. J Virol 2009; 83(6): 2406-16.
  • 9Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC.Mammalian target of rapamycin contributes to the acquired apop- totic resistance of human mesothelioma multicellular spheroids. J Biol Chem 2008; 283(19): 13021-30.
  • 10Pan Q, Liu B, Liu J, Cai R, Wang Y, Qian C. Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adeno- virus carrying TRAIL. Mol Cell Biochem 2007; 304(1-2): 315-23.
中国细胞生物学学报
2011年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部